# **Supporting Information**

# Copper-catalyzed radical process of site selective C-N bond cleavage in twisted amides: Batch and continuous flow method

Karthick Govindan, <sup>[a]</sup> Nian-Qi Chen, <sup>[a]</sup> Hsing-Yin Chen, <sup>[a]</sup> Sodio C. N. Hsu <sup>[a]</sup> and Wei-

Yu Lin<sup>[a-c] \*</sup>

<sup>a</sup> Department of Medicinal and Applied Chemistry, Kaohsiung Medical University,

Kaohsiung 80708, Taiwan, ROC

<sup>b</sup> Department of Medical Research, Kaohsiung Medical University Hospital,

Kaohsiung 80708, Taiwan, ROC

<sup>c</sup> Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan, ROC

Correspondence author Wei-Yu Lin, wylin@Kmu.edu.tw

https://orcid.org/0000-0003-2631-9581

# **Table of Contents**

1	General information	<b>S</b> 3
2	Experimental procedures	S4
2.1	Preparation of Starting Materials	S4
2.2	General experimental procedure for selective C-N bond cleavage in batch	S5
2.3	General experimental procedure for selective C-N bond cleavage in continuous flow method	S6
2.4	Experimental procedure for selective C-N bond cleavage in Gram- scale synthesis	S7
2.5	Experimental procedure for copper-catalyzed C-N bond cleavage	S7
2.6	Experimental procedure for sulfonamide synthesis	<b>S</b> 8
3	Mechanistic evidence for byproduct or intermediates (GC and HRMS data)	<b>S</b> 9
4	Spectral characterization	S10
5	References	S25- S26
6	<sup>1</sup> H and <sup>13</sup> C NMR spectra	S27- S111

#### 1. General Information:

All chemicals were purchased from commercial providers (Sigma Aldrich, Alfa Aesar, TCI, and matrix scientific) and used directly without further purification, unless otherwise noted. Well cleaned and oven dried glassware were used for the experiments. Reaction was monitored by Thin Layer Chromatography (TLC), purchased as pre-coated with silica gel 60 F254 from Merck. Column chromatography was carried out using the silica gel 230-400 mesh (purchased from Merck) with mixture of ethyl acetate/hexane or hexane as the eluent. <sup>1</sup>H NMR spectra were recorded on 400 MHz, <sup>13</sup>C-NMR spectra were recorded on 100 MHz, Varian mercury spectrometer using CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub> as solvent. The spectra were recorded and presented in chemical shifts (ppm) with tetramethylsilane (TMS) used as internal standard. Multiplicities were provided in s (singlet), d (doublet), t (triplet), q (quartet), bs (broad single), m (multiplet), dt (doublet of doublet). Coupling constants (J) were reported in Hz. All the compounds were characterized by ESI mass on Thermo Finnigan (TRACEGC- POLARISQ) and HRMS (ESI+ or FAB+ mode) on JMS-700 spectrometer. Melting points were determined using Fargo instruments.

#### 2. Experimental Procedures

#### 2.1 Preparation of Starting Materials

All starting materials **1a-1z**, **1aa-1aj**, **3a-g**, **3e'**, **3i** were synthesized on 2 mmol scale, according to literature procedure and obtained in 60-88% yield, unless otherwise noted. The <sup>1</sup>H-NMR spectra of all compounds **1a-z**, **1aa-1ae & 1ai-aj**, **3a-g**, **3e'**, **3i** were matched with previous literature. <sup>1-11</sup> The rest of new compounds **1ag**, **1ah** were characterized and the data presented as followed.

#### Procedure for the synthesis of amide substrates 1af, 1ag and 1ah.





Scheme S1 General procedures for the synthesis of amide substrates

1) A 100 mL round-bottom flask was charged with acid (1.0 equiv, 10.0 mmol), dry CH<sub>2</sub>Cl<sub>2</sub> (20.0 mL) and 10 mol% of DMF. The reaction mixture was cooled to 0 °C and stirred for 5 minutes. Then oxalyl chloride (2.0 equiv) was added dropwise to the reaction mixture and stirred at rt for 6-8 h. The resulting mixture was concentrated under reduced pressure to afford acid chloride quantitatively which was used directly without further purification for the next step.

2) An oven-dried round-bottomed flask (50 mL) equipped with a stir bar was charged with amine (5 mmol, 1.0 equiv), triethylamine (typically, 2.0 equiv), 4-dimethylaminopyridine (typically, 0.25 equiv) and dichloromethane (typically, 20 mL), placed under a positive pressure of argon, and subjected to three evacuation/backfilling cycles under high vacuum. Acyl chloride (typically, 1.5 equiv) was added dropwise to the reaction mixture with vigorous stirring at 0 °C, and the reaction mixture was stirred overnight at room temperature. After the indicated time, the reaction mixture was diluted with Et<sub>2</sub>O (10 mL) and filtered. The organic layer was washed with HCl (1.0 N, 10 mL), brine (10 mL), dried, and concentrated. Unless stated otherwise, the crude product was purified by recrystallization (toluene) to give analytically pure product.

2.2 General experimental procedure for selective C-N bond cleavage in batch



Scheme S2 General procedures for the synthesis of primary amides in batch An oven-dried vial was charged with **1a-1z**, **1aa-1aj**, **3e'** (0.2 mmol, 1.0 equiv) and copper (I) chloride (0.01 mmol, 0.05 equiv) in methanol (0.2M). The resulting mixture was allowed to stir at room temperature in an open air for 12h. After completion of reaction extracted with ethyl acetate (3 mL x 5), organic layer combined and washed with brine solution (5 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Hexane/EtOAc, 6/4, silica gel) and obtained as solid up to 35-99% yields. Further, the obtained desired products were characterized by NMR the data were shown given below. 2.3 General experimental procedure for selective C-N bond cleavage in continuous flow



Scheme S3 General procedures for the synthesis of primary amides in continuous flow method

The flow microreactor system of one T-shaped micromixer ( $M_1$  500 µm), one microtube reaction ( $R_1$ ), and two reagents delivering units  $P_1$  (inner diameter = 800 µm, length L = 25 cm),  $P_2$  (inner diameter = 800 µm, length L= 25 cm). A solution of 1a (0.1 M in methanol) and a solution of Cu ( $CO_2CF_3$ )<sub>2</sub>·XH<sub>2</sub>O (0.004 M in methanol) was introduced to  $M_1$  ( $M_1$ ,  $\Phi$  = 500 µm) by syringe pumps. The resulting solution was passed through  $R_1$  ( $\Phi$  = 800 µm, L = 500 cm) at 60 °C. After a steady state was reached (after 1 min), the final product solution was collected for 15 minutes in the vial. The reaction mixture was analysed by GC with 99 % conversion, the solution was extracted with ethyl acetate. The organic phase was dried with MgSO<sub>4</sub>, and the solvent was removed by vacuum. The crude product was purified by column chromatography (Hexane/EtOAc,6/1, silica gel) and obtained **2a** (17.3 mg, 95%).



2.4 Experimental procedure for selective C-N bond cleavage in Gram-scale synthesis

Scheme S4 Experimental procedure for the synthesis of primary amide in gram-scale An oven-dried vial was charged with **1a** (9.21 mmol, 1.0 equiv) and copper (I) chloride (0.4605 mmol, 0.05 equiv) in methanol (0.2M). The resulting mixture was allowed to stir at room temperature in an open air for 12h. After completion of reaction extracted with ethyl acetate (150 mL x 5), organic layer combined and washed with brine solution (50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Hexane/EtOAc, 6/4, silica gel) and obtained as white solid to 89% yield. Further, the obtained desired product was characterized by NMR the data were shown given below

# 2.5 Experimental procedure for copper-catalyzed C-N bond cleavage



Scheme S5 Experimental procedure for the synthesis of dimethyl benzamide An oven-dried vial was charged with **1a** (0.2 mmol, 1.0 equiv) and copper (I) chloride (0.03 mmol, 0.15 equiv) in DMF (0.1M). The resulting mixture was allowed to stir at 120 °C in seal tube under O<sub>2</sub> for 24h. After completion of reaction extracted with ethyl acetate (3 mL x 5), organic layer combined and washed with brine solution (5 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Hexane/EtOAc, 9/1, silica gel) and obtained as solid to 58% yield. Further, the obtained desired product was characterized by NMR the data were shown given below.

#### 2.6 Experimental procedure for sulfonamide synthesis



Scheme S6 Experimental procedure for the synthesis of sulfonamide

An oven-dried vial was charged with **3i** (0.2 mmol, 1.0 equiv) and copper (I) chloride (0.01 mmol, 0.05 equiv) in methanol (0.2M). The resulting mixture was allowed to stir at 60 °C in open air for 12h. After completion of reaction extracted with ethyl acetate (3 mL x 5), organic layer combined and washed with brine solution (5 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Hexane/EtOAc, 9/1, silica gel) and obtained as white solid to 80% yield. Further, the obtained desired product was characterized by NMR the data were shown given below



# 3. Mechanistic evidence for byproduct or intermediates (GC and HRMS data)



4. Characterization data:

# 4.1. Characterization data of starting materials (1ag, 1ah):

# 1-(5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoyl)piperidine-2,6-dione (1ag): Title



compound was synthesized according to the general procedure (Scheme S1), and obtained as semi liquid (570 mg, 55%), [Hexane/EtOAc, 1/1]; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.70 (d, *J* =7.2 Hz, 1H), 6.65 (d, *J* = 8.0 Hz, 1H),

6.62 (s, 1H), 3.94 (t, *J* =4.8 Hz, 2H), 2.65 (t, *J* =5.2 Hz, 4H), 2.30 (s, 3H), 2.17 (s, 3H), 2.02 (q, *J* = 6.4 Hz,2H), 1.87-1.81 (m, 4H), 1.27 (s, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 184.9, 172.0, 157.0,

136.4, 130.24, 123.6, 120.6, 112.0, 67.9, 46.9, 36.5, 32.3, 24.5, 24.2, 21.4, 17.4, 15.8. HRMS (m/z, ESI+) calcd [C<sub>20</sub>H<sub>27</sub>NO<sub>4</sub>Na] + [M+Na] <sup>+</sup> 368.1798, observed 368.1828.

(Z)-1-(docos-13-enoyl)piperidine-2,6-dione (1ah): Title compound was synthesized according to the general procedure (Scheme S1), and obtained as semi liquid (781 mg, 60%),



[Hexane/EtOAc, 1/1]; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 5.30 (t, *J* =4.8 Hz, 2H),

2.64-2.57 (m, 5H), 2.49-2.47 (m, 1H), 1.98-1.94 (m, 4H), 1.87 (q, J = 4.0 Hz, 2H), 1.53-1.46 (m,2H), 1.22 (s, 28H), 0.84 (t, J = 8.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  179.9, 172.7, 130.0, 31.9, 31.7, 29.5, 29.4, 29.3, 29.2, 29.0, 28.4, 27.0, 23.5, 22.5, 17.0, 14.4. HRMS (m/z, ESI-) calcd [C<sub>27</sub>H<sub>46</sub>NO<sub>3</sub>] + [M-H]<sup>-</sup> 432.3522, observed 432.3123.

#### 4.2. Characterization data of products:

#### Benzamide (2a) 12



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (22.3 mg, 92%), [Hexane/EtOAc, 1/1]; Mp.127-129 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.02 (bs, 1H), 7.95-7.92

(m, 2H), 7.60-7.55 (m, 1H), 7.52-7.48 (m, 2H), 7.41 (bs, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.8, 135.1, 132.1, 129.1, 128.4.

#### 4-Methyl benzamide (2b) <sup>13</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (24.3 mg, 90%), [Hexane/EtOAc, 1/1]; Mp.154-156 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.93 (bs, 1H), 7.83

(d, *J* = 8.4 Hz, 2H), 7.31-7.23 (m, 3H), 2.40 (s, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.7, 142.0, 132.4, 129.7, 128.4, 21.9.

#### 4-Ethyl benzamide (2c) 14



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (24.7 mg, 82%), [Hexane/EtOAc, 1/1]; Mp.175-176 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.88 (bs, 1H), 7.79

(d, *J* = 8 Hz, 2H), 7.27 (d, *J* = 8 Hz, 3H) 2.64 (q, *J* = 8.0 Hz, 2H), 1.19 (t, *J* = 8Hz, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.2,147.6, 132.2, 28.4, 15.8.

#### 4-Methoxy benzamide (2d) <sup>12</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (28.7 mg, 95%), [Hexane/EtOAc, 1/1]; Mp.161-163 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )

δ 7.85–7.83 (m, 3H), 7.17 (bs, 1H), 6.97 (d, *J* = 8.8 Hz, 2H), 3.80 (s, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.4, 161.6, 129.3, 126.5, 113.4, 55.3

#### 3,5-dimethoxy benzamide (2e) <sup>15</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (33 mg, 91%), [Hexane/EtOAc, 1/1]; Mp.169-170 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )

δ 7.93 (bs, 1H), 7.35 (bs, 1H), 7.03 (d, *J* = 2.0 Hz, 2H), 6.63 (t, *J* = 2.0 Hz, 1H), 3.77 (s, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.9, 160.7, 136.9, 105.9, 103.6, 55.8.

#### 3,4-dimethoxy benzamide (2f) <sup>16</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (32.2 mg, 89%), [Hexane/EtOAc, 1/1]; Mp.162-163 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )

δ 7.85 (bs, 1H), 7.51-7.45 (m, 2H), 7.18 (bs, 1H), 6.99 (d, *J* = 8.4 Hz, 1H), 3.79 (d, *J* = 3.6 Hz, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.9, 151.7, 148.6, 127.0, 121.2, 111.4, 111.3, 56.0.

# 4-(tert-butyl) benzamide (2g) <sup>17</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (33.3 mg, 94%), [Hexane/EtOAc, 1/1]; Mp.165-167 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>)

δ 7.95 (bs, 1H), 7.86 (d, *c*), 7.51 (d, *J* = 8.4 Hz, 2H), 7.32 (bs, 1H), 1.35 (s, 9H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.8, 154.9, 132.5, 128.3, 125.9, 35.5, 31.9.

#### 1-Napthamide (2h)<sup>18</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (33.9 mg, 99%), [Hexane/EtOAc, 1/1]; Mp.200-201 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.32 – 8.29 (m, 1H),

8.01–7.95 (m, 3H), 7.63 (dd, J = 7.2 Hz, 1.2 Hz, 1H), 7.59–7.51 (m, 4H);

<sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 171.0, 135.1, 133.6, 130.2, 130.1, 128.6, 127.0, 126.5, 126.0, 125.6, 125.4.

## [1,1'-biphenyl]-4-carboxamide (2i) <sup>19</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (36.3 mg, 92%), [Hexane/EtOAc, 1/1]; Mp.220-221 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>)

δ 7.98 (bs, 1H), 7.93-7.92 (m, 2H), 7.72-7.68 (m, 4H), 7.48-7.45 (2H, m), 7.37-7.34 (m, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.0, 143.2, 139.7, 133.6, 129.5, 128.6, 128.5, 127.4, 127.0. **4-Fluoro benzamide (2i)** <sup>13</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (23.1 mg, 83%), [Hexane/EtOAc, 1/1]; Mp.138-140 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$ 

7.98 (bs, 1H), 7.96 – 7.91 (m, 2H), 7.38 (bs, 1H), 7.31 – 7.25 (m, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  166.8, 165.1 (d, <sup>1</sup>J = 247 Hz), 130.7, 130.1 (d, <sup>3</sup>J = 8.6 Hz), 115.2 (d, <sup>2</sup>J = 22 Hz).

# 4-Bromo benzamide (2k) 20



Title compound was synthesized according to the general procedure (Scheme S2), and obtained as white solid (32.2 mg, 81%), [Hexane/EtOAc, 1/1]; Mp.208-209 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$ 

8.04 (bs, 1H), 8.02-7.97 (m, 2H), 7.44 (bs, 1H), 7.36-7.31 (m, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO*d*<sub>6</sub>) δ 166.9, 133.4, 131.2, 129.6, 125.0.

#### 4-Chloro benzamide (2I)<sup>20</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (24.2 mg, 78%), [Hexane/EtOAc, 1/1]; Mp.192-194 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.10 (bs, 1H),

7.95 (d, *J* = 8.0 Hz, 2H), 7.59-7.56 (m, 2H), 7.51 (bs, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.8, 137.0, 134.0, 130.3, 129.2.

#### 2-lodo benzamide (2m)<sup>17</sup>

Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (49.4 mg, 97%), [Hexane/EtOAc, 1/1]; Mp.192-194 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.87 (dd, J = 0.8Hz, J= 8Hz, 1H), 7.81(bs, 1H), 7.50 (bs, 1H), 7.42 (td, J = 7.2 Hz, J = 0.8Hz, 1H), 7.33 (td, J = 7.6 Hz, J = 1.6Hz,1H), 7.14 (td, J = 7.6 Hz, J = 1.6Hz,1H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  170.7, 143.1, 139.1, 130.6, 127.9, 127.8, 93.1.

#### 3,4-Difluoro benzamide (2n)<sup>21</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (23 mg, 73%), [Hexane/EtOAc, 1/1]; Mp.150-152 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.12 (bs, 1H), 7.99-7.93 (m, 1H), 7.84-7.81 (m, 1H), 7.62-7.55 (m, 2H); <sup>13</sup>C-NMR (100

MHz, DMSO-*d*<sub>6</sub>) δ 167.6, 139.0, 132.1 (q, *J* = 63.9 Hz), 129.1 (d, *J* = 28.6 Hz), 126.2 (d, *J* = 2.9 Hz), 122.2 (d, *J* = 270.7 Hz).

#### 4-(trifluoromethyl) benzamide (20)<sup>21</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (35.2 mg, 93%), [Hexane/EtOAc, 1/1]; Mp.206-208 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )

δ 8.24 (bs, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.89 (d, J = 8.4 Hz, 2H), 7.67 (bs, 1H); <sup>13</sup>C-NMR (100

MHz, DMSO-*d*<sub>6</sub>) δ 167.6, 139.0, 132.1 (q, *J* = 63.9 Hz), 129.1 (d, *J* = 28.6 Hz), 126.2 (d, *J* = 2.9 Hz), 122.2 (d, *J* = 270.7 Hz).

#### 4-Cyano benzamide (2p) <sup>17</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (22.8 mg, 78%), [Hexane/EtOAc, 1/1]; Mp.224-226 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$ 

8.26 (bs, 1H), 8.09-8.07 (m, 2H), 8.02-7.99 (m, 2H), 7.72 (bs, 1H); <sup>13</sup>C-NMR (100 MHz, DMSOd<sub>6</sub>) δ 167.3, 139.2, 133.3, 129.2, 119.3, 114.6.

#### Methyl 4-carbamoylbenzoate (2q) <sup>22</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (28.6 mg, 80%), [Hexane/EtOAc, 1/1]; Mp.201-203 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-

d<sub>6</sub>) δ 8.14(bs, 1H), 8.03– 7.97(m, 4H), 7.56 (bs, 1H), 3.88 (s, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-

*d*<sub>6</sub>) δ 167.0, 165.7, 138.4, 131.8, 129.0, 127.8, 52.4.

#### Cinnamamide (2r) 13



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (28.5 mg, 97%), [Hexane/EtOAc, 3/2]; Mp.146-148 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>)

δ 7.57 – 7.54 (m, 3H), 7.43 – 7.35 (m, 4H), 7.10 (bs, 1H), 6.61 (d, *J* = 16.0 Hz, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 166.6, 139.1, 134.9, 129.4, 128.9, 127.5, 122.3.

#### 2-(phenyl ethynyl) benzamide (2s) <sup>23 24</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (43.8 mg, 99%), [Hexane/EtOAc, 3/2]; Mp.146-148 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.81 (bs, 1H), 7.59–7.48 (m, 4H), 7.46–7.40 (m, 4H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$ 

169.1,139.5, 132.4, 131.3, 129.6, 128.9, 128.7, 128.5, 127.7, 122.5, 119.7, 92.7, 88.1.

#### Benzofuran-2-carboxamide (2t) <sup>19</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (24.8 mg, 77%), [Hexane/EtOAc, 3/2]; Mp.186-188 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  8.17 (bs, 1H), 7.82

(d, J = 8.0 Hz, 1H), 7.74 (bs, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.60 (s, 1H), 7.51 (t, J = 7.8 Hz, 1H),

7.38 (t, J = 7.4 Hz, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-d<sub>6</sub>) δ 160.7, 155.2, 150.3, 128.1, 127.7, 124.5, 123.6, 112.7, 110.5.

#### Furan-2-carboxamide (2u)<sup>25</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (19.5 mg, 88%), [Hexane/EtOAc, 3/2]; Mp.140-142 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.85 (bs, 1H), 7.80 (bs, 1H),

7.41 (s, 1H), 7.15 (d, *J* = 3.2 Hz, 1H), 6.66-6.64 (m, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 160.3, 149.0, 145.9, 114.5, 112.7.

#### Benzo[d] [1,3] dioxole-5-carboxamide (2v) <sup>22</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (27.4 mg, 83%), [Hexane/EtOAc, 3/2]; Mp.189-190 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.81 (bs, 1H),

7.46 (dd, *J* = 8.0 Hz, *J* = 1.6 Hz, 1H), 7.40 (d, *J* = 1.2 Hz, 1H), 7.23 (bs, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 6.08 (s, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.5, 150.2, 147.7, 128.8, 123.0, 108.2, 108.0, 102.1.

## Thiophene-2-carboxamide (2w)<sup>20</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (24.1 mg, 95%), [Hexane/EtOAc, 3/2]; Mp.197-199 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.95 (bs, 1H), 7.74–7.73 (m,

2H), 7.36 (bs, 1H), 7.13(dd, *J* = 0.8Hz, *J* = 4.8Hz, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 162.9, 140.3, 131.0, 128.6, 127.9.

#### 9H-carbazole-9-carboxamide (2x)<sup>26</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (26 mg, 62%), [Hexane/EtOAc, 3/2]; Mp.248-250 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.17 (d, J = 7.6 Hz, 2H),

8.01 (d, *J* = 8.4 Hz, 2H), 7.74 (bs, 2H), 7.51-7.47 (m, 2H), 7.35-7.31 (m, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 153.8, 138.5, 127.1, 124.5, 122.2, 120.6, 114.6.

# Cyclohexane carboxamide (2y) <sup>12</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (17.8 mg, 70%), [Hexane/EtOAc, 3/2]; Mp.183-185 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.12 (bs, 1H), 6.60 (bs,

1H), 2.08-2.00 (m, 1H), 1.70-1.58 (m, 5H), 1.33-1.07 (m, 5H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 177.8, 44.1, 29.6, 26.0, 25.8.

#### Adamantane-1-carboxamide (2z) <sup>27</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (25.8 mg, 72%), [Hexane/EtOAc, 3/2]; Mp.187-188 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  6.90 (bs, 1H), 6.63 (bs, 1H),

1.92 (s, 3H), 1.73–1.72 (m, 6H), 1.67–1.59 (m, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 179.7, 36.6, 28.1.

## Pivalamide (2aa)<sup>28</sup>

Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (12.7 mg, 63%), [Hexane/EtOAc, 3/2]; Mp.153-154 °C; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.6 (bs, 2H), 1.22 (s, 9H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  181.3, 38.6, 27.6.

#### Octanamide (2ab) 29



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (19.5 mg, 68%), [Hexane/EtOAc,

3/2]; Mp.110-111 °C; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ 6.59 (bs, 1H), 5.63 (bs, 1H), 2.31 (t, *J* = 7.2

Hz, 1H), 2.21 (t, *J* = 7.2 Hz, 1H), 1.70-1.58 (m, 2H), 1.30-1.24 (m, 8H), 0.88-0.82 (m, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 177.1, 36.0, 31.6, 29.1, 25.5, 24.8, 22.6, 14.0.

#### Decanamide (2ac) 30

Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (24.3 mg, 71%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.64 (bs, 1H), 5.42 (bs, 1H), 2.22 (t, *J* = 7.8 Hz, 2H), 1.67-1.60 (m, 2H), 1.30-1.27 (m, 12H), 0.89-0.86 (m, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  175.8, 36.0, 31.8, 29.4, 29.3, 29.2, 25.5, 24.8, 22.6, 14.1.

6-(3-((3r, 5r, 7r)-adamantan-1-yl)-4-methoxyphenyl)-2-napthamide (2ad) <sup>31</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (49.3 mg, 60%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.48 (s, 1H), 8.19 (s, 1H), 8.11 (bs, 1H), 8.06-8.03 (m, 2H), 7.96 (dd, *J*= 8.4 Hz, *J* = 1.6 Hz, 1H), 7.87

(dd, *J* = 8.4 Hz, *J* = 1.6 Hz, 1H), 7.64 (dd, *J* = 8.4 Hz, *J* = 2.4 Hz, 1H), 7.57 (d, *J* = 2.4 Hz, 1H), 7.44 (bs, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 3.87 (s, 3H), 2.14 (s, 6H), 2.07 (s, 3H), 1.76 (s, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 168.36, 158.94, 139.91, 138.47, 135.12, 132.09, 131.68, 131.36, 129.87, 128.40, 127.98, 126.23, 126.09, 125.45, 125.15, 124.47, 113.18, 55.81, 49.30, 37.06, 37.01, 28.85.

#### 4-(N, N-dipropylsulfamoyl) benzamide (2ae) <sup>31</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (28.4 mg, 50%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.17 (bs, 1H), 8.03 (d, *J* = 8.4 Hz, 2H), 7.86 (d, *J* =

8.4 Hz, 2H), 7.60 (bs, 1H), 3.04 (t, *J* = 7.6 Hz, 3H), 1.49-1.44 (m, 4H), 0.81 (t, *J* = 7.2 Hz, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.11, 142.17, 138.28, 128.85, 127.18, 50.07, 31.77, 22.06, 11.41.

# 3, 4, 5-trimethoxybenzamide (2af)<sup>22</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (23.6 mg, 56%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.95(bs, 1H), 7.32(bs, 1H), 7.21 (s, 2H), 3.81 (s, 6H), 3.69 (d, *J* = 0.4

Hz, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 167.3, 152.5, 139.9, 129.4, 105.1, 60.0, 56.0.

#### 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide (2ag)<sup>31</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (36.4 mg, 73%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400

MHz, DMSO- $d_6$ )  $\delta$  7.02(bs, 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.77 (bs, 1H), 6.70 (s, 1H), 6.61 (d, J = 7.6 Hz,1H), 3.87 (t, J = 6.0 Hz,2H), 2.24 (s,3H), 2.07 (s, 3H), 1.65-1.54 (m, 4H), 1.08 (s, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  179.3, 157.0, 136.5, 130.5, 122.9, 120.9, 112.5, 68.2, 41.5, 37.3, 25.8, 25.2, 21.5, 16.0.

#### (E)-docos-13-enamide (2ah)<sup>32</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid

(41.8 mg, 62%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$ 7.18(bs, 1H), 6.63 (bs, 1H), 5.33-5.31 (m, 2H), 2.02-1.96 (m, 4H), 1.46 (t, J = 4.8 Hz,2H), 1.31-1.23 (m, 24H), 0.86-0.84 (m, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  174.19, 129.57, 35.07, 31.22, 29.03, 28.97, 28.92, 28.81, 28.77, 28.69, 28.63, 28.52, 26.50, 25.05, 22.03, 13.87. HRMS (m/z, ESI-) calcd [C<sub>22</sub>H<sub>42</sub>NO] + [M-H] <sup>-</sup> 336.3222, observed 336.5433.

#### 3-(4,5-diphenyloxazol-2-yl) propanamide (2ai) <sup>33</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (26.3 mg, 45%), [Hexane/EtOAc, 3/2]; Mp.100-102 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.57-7.55 (m, 2H), 7.54-7.52 (m, 2H), 7.45-7.42 (m,

3H), 7.41-7.38 (m, 2H), 7.37-7.34 (m, 1H), 6.87 (bs, 1H), 3.03 (t, J = 4.8 Hz, 2H), 2.62 (t, J = 5.0 Hz,2H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  172.92, 163.26, 144.92, 134.76, 132.51, 129.37, 129.20, 129.06, 128.93, 128.55, 127.79, 126.76, 31.82, 23.61. HRMS (m/z, ESI+) calcd [C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>] + [M+H] <sup>+</sup> 293.1278, observed 293.2138.

(R)-4-((5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7,12-trioxohexadecahydro-1H-

cyclopenta[a]phenanthren-17-yl) pentanamide (2aj)<sup>23</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (43.3 mg, 54%); Mp.228-230 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.18 (bs, 1H), 6.60 (bs, 1H), 3.04-2.92

(m, 2H), 2.83-2.77 (m, 1H), 2.43-2.39 (m, 1H), 2.33-2.06 (m, 5H), 1.95-1.66 (m, 9H), 1.50-1.42 (m, 1H), 1.29-1.13 (m, 8H), 0.97 (s, 3H), 0.73-0.70 (m, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO*d*<sub>6</sub>) δ 212.4, 210.1, 210.0, 175.3, 56.7, 51.7, 48.4, 46.5, 45.9, 45.0, 44.5, 43.0, 36.6, 36.1, 35.5, 35.1, 31.6, 30.9, 27.7, 25.1, 21.6, 19.2, 1.

(3S,10R,13S)-17-((R)-1-amino-1-oxopropan-2-yl)-10,13-dimethyl-

2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate (2ak) <sup>34</sup>



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (55 mg, 71%); Mp.236-238 °C; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.37-5.36 (m, 3H), 2.32-2.31 (m, 2H), 2.21-2.17 (m, 1H), 2.02

(s, 3H), 1.97-1.94 (m, 2H), 1.86-1.83 (m, 3H), 1.66-1.53 (m, 6H), 1.47-1.41 (m, 2H), 1.29-1.21 (m, 5H), 1.13-1.06 (m, 3H), 1.01-0.97 (m, 4H), 0.70 (s, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 179.1, 170.5, 139.6, 122.5, 73.9, 56.2, 52.8, 49.9, 44.1, 42.3, 39.5, 38.1, 36.9, 36.6, 31.9, 31.8, 29.7, 27.7, 27.6, 24.3, 21.4, 20.9, 19.3, 17.7, 12.0.

#### N, N-dimethyl benzamide (4a) 35



Title compound was synthesized according to the general procedure (Scheme S5), and obtain as white solid (17.3 mg, 58%), [Hexane/EtOAc, 3/2]; Mp.43-44 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  7.44–7.37 (m, 5H), 2.98 (s, 3H),

2.89 (s, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 170.1, 136.5, 129.3, 128.3, 126.9, 34.7.

# Thiobenzamide (2a') 36



Title compound was synthesized according to the general procedure (Scheme S2), and obtain as white solid (16.4 mg, 60%), [Hexane/EtOAc, 3/2]; Mp.114-115 °C; <sup>1</sup>H-NMR (400 MHz, DMSO- $d_6$ )  $\delta$  9.87 (bs, 1H), 9.49 (bs, 1H),

7.89–7.87 (m, 2H), 7.52–7.48 (m, 1H), 7.43–7.39 (m, 2H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 200.2, 139.5, 131.1, 127.9, 127.3.

#### 4-methylbenzenesulfonamide (4i) <sup>37</sup>



Title compound was synthesized according to the general procedure (Scheme S6), and obtain as white solid (27.4 mg, 80%), [Hexane/EtOAc,

3/2]; Mp.137-138 °C; <sup>1</sup>H-NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 7.71–7.69 (m, 2H),

7.37–7.35 (m, 2H), 7.26 (bs, 2H), 2.37 (s, 3H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 142.3, 141.9, 129.7, 126.0, 21.4.

# 5. References

- 1. F. Bie, X. Liu, H. Cao, Y. Shi, T. Zhou, M. Szostak and C. Liu, *Org. Lett.*, 2021, **23**, 8098-8103.
- 2. K. Govindan, N.-Q. Chen, Y.-W. Chuang and W.-Y. Lin, *Org. Lett.*, 2021, **23**, 9419-9424.
- 3. K. Govindan and W.-Y. Lin, *Org. Lett.*, 2021, **23**, 1600-1605.
- 4. M. Kandasamy, A. J. J. Amalraj, G. Perumal, B. Ganesan, G. C. Senadi and W.-Y. Lin, *J. Flow Chem.*, 2020, **10**, 507-515.
- 5. S.-C. Lee, L. Guo, H. Yue, H.-H. Liao and M. Rueping, *Synlett*, 2017, **28**, 2594-2598.
- 6. Y. Liu, M. Achtenhagen, R. Liu and M. Szostak, Org. Biomol. Chem., 2018, 16, 1322-1329.
- 7. G. Meng and M. Szostak, Org. Biomol. Chem., 2016, **14**, 5690-5707.
- 8. M. M. Rahman, C. Liu, E. Bisz, B. e. Dziuk, R. Lalancette, Q. Wang, H. Chen, R. Szostak and M. Szostak, *J. Org. Chem.*, 2020, **85**, 5475-5485.
- 9. S. Shi and M. Szostak, *Org. Lett.*, 2017, **19**, 3095-3098.
- 10. W. Srimontree, A. Chatupheeraphat, H.-H. Liao and M. Rueping, *Org. Lett.*, 2017, **19**, 3091-3094.
- 11. J. Zhang, P. Zhang, L. Shao, R. Wang, Y. Ma and M. Szostak, *Angew. Chem. Int. Ed.*, 2022, **61**, e202114146.
- 12. R. González-Fernández, P. Crochet, V. Cadierno, M. I. Menéndez and R. López, *Chem. Eur. J.*, 2017, **23**, 15210-15221.
- 13. P. Marcé, J. Lynch, A. J. Blacker and J. M. Williams, *Chem. Comm.*, 2016, **52**, 1436-1438.
- 14. N. S. Thirukovela, R. Balaboina, S. Kankala, R. Vadde and C. S. Vasam, *Tetrahedron*, 2019, **75**, 2637-2641.
- 15. X.-F. Wu, H. Neumann, S. Neumann and M. Beller, *Tetrahedron Lett.*, 2013, **54**, 3040-3042.
- 16. M. ChennaáReddy, *Chem. Comm.*, 2013, **49**, 6060-6062.
- 17. S. Shimokawa, Y. Kawagoe, K. Moriyama and H. Togo, *Org. Lett.*, 2016, **18**, 784-787.
- 18. F.-L. Yang, X. Zhu, D.-K. Rao, X.-N. Cao, K. Li, Y. Xu, X.-Q. Hao and M.-P. Song, *RSC Adv.*, 2016, **6**, 37093-37098.
- 19. C. Tang and N. Jiao, *Angew. Chem. Int. Ed.*, 2014, **126**, 6646-6650.
- 20. N. Wang, P. Ma, J. Xie and J. Zhang, *Molecular Diversity*, 2021, **25**, 1131-1136.
- 21. R. Ray, A. S. Hazari, S. Chandra, D. Maiti and G. K. Lahiri, *Chem. Eur. J.*, 2018, **24**, 1067-1071.
- 22. D. D. S. Sharley and J. M. Williams, *Tetrahedron Lett.*, 2017, **58**, 4090-4093.
- 23. M. Jithunsa, M. Ueda and O. Miyata, *Org. Lett.*, 2011, **13**, 518-521.
- 24. S. Mehta and D. Brahmchari, J. Org. Chem., 2019, **84**, 5492-5503.
- 25. P. N. Borase, P. B. Thale and G. S. Shankarling, *ChemistrySelect*, 2018, **3**, 5660-5666.
- 26. N. Konstandaras, M. H. Dunn, M. S. Guerry, C. D. Barnett, M. L. Cole and J. B. Harper, *Org. Biomol. Chem.*, 2020, **18**, 66-75.
- 27. T. A. Reekie, C. M. Williams, L. M. Rendina and M. Kassiou, *J. Med. Chem.*, 2018, **62**, 1078-1095.
- 28. B. Guo, J. G. de Vries and E. Otten, *Chemical science*, 2019, **10**, 10647-10652.
- 29. S. T. Chill and R. C. Mebane, *Synthetic Communications*<sup>®</sup>, 2010, **40**, 2014-2017.
- 30. M. H. Al-Huniti, J. Rivera-Chávez, K. L. Colón, J. L. Stanley, J. E. Burdette, C. J. Pearce, N. H. Oberlies and M. P. Croatt, *Org. Lett.*, 2018, **20**, 6046-6050.
- 31. Y.-Q. Miao, J.-X. Kang, Y.-N. Ma and X. Chen, *Green Chem.*, 2021, **23**, 3595-3599.
- 32. E. B. Divito, A. P. Davic, M. E. Johnson and M. Cascio, *Anal. Chem.*, 2012, **84**, 2388-2394.

- 33. J. S. Kramer, S. Woltersdorf, T. Duflot, K. Hiesinger, F. F. Lillich, F. Knöll, S. K. Wittmann, F.-M. Klingler, S. Brunst and A. Chaikuad, *J. Med. Chem.*, 2019, **62**, 8443-8460.
- 34. H. H. Wasserman and P. S. Wharton, J. Am. Chem. Soc., 1960, 82, 661-665.
- 35. J. Wang, H. Hou, Y. Hu, J. Lin, M. Wu, Z. Zheng and X. Xu, *Tetrahedron Lett.*, 2021, **65**, 152801.
- 36. H. R. Lagiakos, A. Walker, M.-I. Aguilar and P. Perlmutter, *Tetrahedron Lett.*, 2011, **52**, 5131-5132.
- 37. D. Azarifar and F. Soleimanei, *RSC Adv.*, 2014, **4**, 12119-12126.

# <sup>1</sup>H and <sup>13</sup>C NMR spectra











Solvent : CDCl<sub>3</sub> Spectrometer Frequency : 400 MHz









 $\begin{array}{l} \text{Solvent}: \text{CDCl}_3 \\ \text{Spectrometer Frequency}: 100 \text{ MHz} \end{array}$ 






























200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10	0 C

































































- 52.359






















				U		****			М			
200.0 190.0 180.0	170.0 160.0	150.0	140.0 130.0	120.0 110.0	100.0 90.0	80.0 70.	0 60.0	50.0 4	40.0 30.0	20.0	10.0	0
X : parts per Million : Carbon13	159.840	148.523 145.462		114.036						S	573	

























200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0	0
X: parts per Million : Carbon 13	





200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	90.0	80.0	70.0	60.0	50.0	40.0	30.0	20.0	10.0	0
		- 277														138	636 <sup>-</sup> 984 -	t		
		177.														44.	29. 25.		\$81	
X : parts pe	r Million : Ca	bon13																		



- 28.109











2ab

Solvent : CDCl<sub>3</sub> Spectrometer Frequency : 400 MHz



2ab

Solvent : CDCl<sub>3</sub> Spectrometer Frequency : 100 MHz



Solvent : CDCl<sub>3</sub> Spectrometer Frequency : 400 MHz





Solvent :  $CDCl_3$ Spectrometer Frequency : 100 MHz







fl (ppm)













<sup>5.0 4.5</sup> f1 (ppm) 5.5















## $\begin{array}{c} \text{Solvent}:\text{CDCl}_3\\ \text{Spectrometer Frequency}:400\text{ MHz} \end{array}$











 $\begin{array}{l} \text{Solvent}: \text{CDCl}_3\\ \text{Spectrometer Frequency}: 100 \ \text{MHz} \end{array}$ 



- 12.040









[]






## Solvent : DMSO $-d_6$ Spectrometer Frequency : 100 MHz

- 200.224







Solvent : DMSO  $-d_6$ Spectrometer Frequency : 400 MHz - 2.371







Solvent : DMSO  $-d_6$ Spectrometer Frequency : 100 MHz



